- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04121845
CoROnary SinuS Reducer implantatiOn for ischemiA reDuction (CrossRoad)
July 21, 2022 updated by: Matjaž Bunc, University Medical Centre Ljubljana
The Influence of Coronary Sinus Reducer Implantation on Exertional Capacity, Extent of Myocardial Ischemia and hrECG Markers of Arrhythmogenicity in Patients With Refractory Angina Pectoris
Patients with refractory angina pectoris have low quality of life and reduced exertional capacity.
Studies have shown that the coronary sinus reducer (CSR) implantation improves the quality of life.
However, to date there are no firm objective data on improvement of exertional capacity.
Studies have shown a large influence of placebo effect after interventional procedures, which is even more pronounced than in medically treated patients.
As angina pectoris presents entirely subjective perception of chest discomfort, its improvement may be influenced by this effect in up to 30 %.
The investigators will study weather the CSR implantation improves aerobic exertional capacity in comparison to optimal medical therapy alone.
Further, the investigators will explore the extent of myocardial reversible ischemia reduction and possible influence on hrECG markers of left ventricular arrhythmogenicity.
40 patients with refractory angina CCS class (Canadian cardiovascular society) II-IV and confirmed reversible ischemia will be included.
Patients will be randomized into two groups.
The first group will undergo CSR implantation procedure.
The second group will present a sham control group with placebo procedure.
At inclusion and after 6 months the investigators will perform cardiopulmonary exercise test (CPET), single photon emission tomography for detection of reversible ischemia (SPECT), high resolution ECG (hrECG), echocardiography and asses the subjective burden of angina according to CCS score and the quality of life according to the Seattle angina Questionnaire (SAQ).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ljubljana, Slovenia, 1000
- University Medical Centre Ljubljana
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 83 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- angina pectoris CCS class II-IV
- receiving optimal medical therapy for at least one month
- confirmed reversible myocardial ischemia in left anterior descending coronary artery (LAD) and/or left circumflex coronary artery (LCX) territory by SPECT
- not candidate for percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
Exclusion Criteria:
- recent non stable angina pectoris (within 1 months)
- recent acute coronary syndrome (within 3 months)
- recent successful PCI and/or CABG (within 6 months)
- decompensated heart failure and/or recent (within 3 months) hospitalization due to heart failure
- severe heart valve(s) disease
- advanced chronic obstructive pulmonary disease (COPD) or poorly managed asthma
- peripheral arterial disease, musculoskeletal disorder or central nervous system disease which preclude exercise testing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment group
Coronary sinus reducer implantation through right internal jugular vein.
|
Coronary sinus reducer device (Neovasc, Richomnd, Canada) implantation in the coronary sinus.
The procedure is performed in the cardiac catheterization laboratory through right internal jugular vein.
|
Sham Comparator: Sham group
Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
|
Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of CSR versus placebo procedure on exertional capacity measured by maximal oxygen consumption (VO2) during cardio-pulmonary exercise testing.
Time Frame: 6 months
|
Maximal oxygen consumption on cycle spiroergometry using the same ramp exercise protocol during the same part of the day.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of CSR versus placebo procedure on exercise duration time during cardio-pulmonary exercise testing.
Time Frame: 6 months
|
Exercise duration time on cycle spiroergometry using the same continuous exercise protocol during the same part of the day.
|
6 months
|
Change in the extent of myocardial reversible ischemia calculated by single-photon emission computed tomography (dynamic scintigraphy).
Time Frame: 6 months
|
Dynamic myocardial scintigraphy with the use of a 4 segment model of the left ventricle for calculation of absolute regional perfusion (ml/g/min) during rest and during pharmacologic stress.
Change in the extent of myocardial reversible ischemia calculated by single-photon emission computed tomography.
|
6 months
|
Change in the extent of myocardial reversible ischemia calculated by single-photon emission computed tomography (static scintigraphy).
Time Frame: 6 months
|
Static myocardial scintigraphy with the use of a 17 segment model for the relative calculation of regional perfusion during rest and pharmacologic stress.
|
6 months
|
Change in RR interval variability as assessed by hrECG.
Time Frame: 6 months
|
5 min recording of hrECG (1000 Hz) for the calculation of RR interval variability.
|
6 months
|
Change in late potentials as assessed by hrECG.
Time Frame: 6 months
|
5 min recording of hrECG (1000 Hz) for the calculation of late potentials.
|
6 months
|
Change in QT variability as assessed by hrECG.
Time Frame: 6 months
|
5 min recording of hrECG (1000 Hz) for determination of QT variability.
|
6 months
|
Change in Canadian Cardiovascular Society angina pectoris class (CCS).
Time Frame: 3 months, 6 months
|
Change in CCS class I-IV. Acco
|
3 months, 6 months
|
Impact of CSR versus placebo procedure on quality of life according to Seattle angina questionnaire (SAQ).
Time Frame: 3 months, 6 months
|
Change in each of the five categories: Physical Limitation Scale (range 1-100), Anginal Stability Scale (range 1-100), Anginal Frequency Scale (range 1-100), Treatment Satisfaction Scale (range 1-100), Disease Perception Scale (range 1-100).
Higher values in scale represent better outcome.
Subscales are not combined.
|
3 months, 6 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Influence of CSR implantation on echocardiographically assessed left ventricular elastance.
Time Frame: 6 months
|
6 months
|
Influence of CSR implantation on diastolic strain.
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Matjaž Bunc, Prof., University Medical Centre Ljubljana, Slovenia
- Study Chair: David Žižek, Assoc. Prof., University Medical Centre Ljubljana, Slovenia
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Verheye S, Jolicoeur EM, Behan MW, Pettersson T, Sainsbury P, Hill J, Vrolix M, Agostoni P, Engstrom T, Labinaz M, de Silva R, Schwartz M, Meyten N, Uren NG, Doucet S, Tanguay JF, Lindsay S, Henry TD, White CJ, Edelman ER, Banai S. Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med. 2015 Feb 5;372(6):519-27. doi: 10.1056/NEJMoa1402556.
- Banai S, Ben Muvhar S, Parikh KH, Medina A, Sievert H, Seth A, Tsehori J, Paz Y, Sheinfeld A, Keren G. Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study. J Am Coll Cardiol. 2007 May 1;49(17):1783-9. doi: 10.1016/j.jacc.2007.01.061.
- Konigstein M, Verheye S, Jolicoeur EM, Banai S. Narrowing of the Coronary Sinus: A Device-Based Therapy for Persistent Angina Pectoris. Cardiol Rev. 2016 Sep-Oct;24(5):238-43. doi: 10.1097/CRD.0000000000000101.
- Abawi M, Nijhoff F, Stella PR, Voskuil M, Benedetto D, Doevendans PA, Agostoni P. Safety and efficacy of a device to narrow the coronary sinus for the treatment of refractory angina: A single-centre real-world experience. Neth Heart J. 2016 Sep;24(9):544-51. doi: 10.1007/s12471-016-0862-2.
- Konigstein M, Meyten N, Verheye S, Schwartz M, Banai S. Transcatheter treatment for refractory angina with the Coronary Sinus Reducer. EuroIntervention. 2014 Feb;9(10):1158-64. doi: 10.4244/EIJV9I10A196.
- Mannheimer C, Camici P, Chester MR, Collins A, DeJongste M, Eliasson T, Follath F, Hellemans I, Herlitz J, Luscher T, Pasic M, Thelle D. The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J. 2002 Mar;23(5):355-70. doi: 10.1053/euhj.2001.2706. No abstract available.
- Henry TD, Satran D, Hodges JS, Johnson RK, Poulose AK, Campbell AR, Garberich RF, Bart BA, Olson RE, Boisjolie CR, Harvey KL, Arndt TL, Traverse JH. Long-term survival in patients with refractory angina. Eur Heart J. 2013 Sep;34(34):2683-8. doi: 10.1093/eurheartj/eht165. Epub 2013 May 12.
- Giannini F, Aurelio A, Jabbour RJ, Ferri L, Colombo A, Latib A. The coronary sinus reducer: clinical evidence and technical aspects. Expert Rev Cardiovasc Ther. 2017 Jan;15(1):47-58. doi: 10.1080/14779072.2017.1270755.
- Myers J, Froelicher VF. Optimizing the exercise test for pharmacological investigations. Circulation. 1990 Nov;82(5):1839-46. doi: 10.1161/01.cir.82.5.1839.
- Kralios AC, Nappi JM, Tsagaris TJ, Kralios FA, Kuida H. Paradoxical increase of ventricular fibrillation threshold in response to coronary sinus obstruction. Am Heart J. 1988 Feb;115(2):334-40. doi: 10.1016/0002-8703(88)90479-6.
- Kralios AC, Anderson FL, Kralios FA. Protective effect of coronary sinus obstruction from primary ischemia-induced ventricular fibrillation in the dog. Am Heart J. 1993 Apr;125(4):987-95. doi: 10.1016/0002-8703(93)90105-i.
- De Maria GL, Kassimis G, Raina T, Banning AP. Reconsidering the back door approach by targeting the coronary sinus in ischaemic heart disease. Heart. 2016 Aug 15;102(16):1263-9. doi: 10.1136/heartjnl-2016-309642. Epub 2016 Jun 10.
- Baldetti L, Colombo A, Banai S, Latib A, Esposito A, Palmisano A, Giannini F. Coronary sinus Reducer non-responders: insights and perspectives. EuroIntervention. 2018 Feb 20;13(14):1667-1669. doi: 10.4244/EIJ-D-17-00626.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2019
Primary Completion (Actual)
December 31, 2021
Study Completion (Actual)
June 30, 2022
Study Registration Dates
First Submitted
October 6, 2019
First Submitted That Met QC Criteria
October 8, 2019
First Posted (Actual)
October 10, 2019
Study Record Updates
Last Update Posted (Actual)
July 25, 2022
Last Update Submitted That Met QC Criteria
July 21, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CrossRoad
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
All IPD that underlie results in a publication All IPD on special request
IPD Sharing Time Frame
After study completion and results publication.
Not limited.
IPD Sharing Access Criteria
All IPD that underlie results in a publication on editor/researcher request.
All IPD on special request.
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory Angina Pectoris
-
Barts & The London NHS TrustRecruitingRefractory Angina | Refractory Angina PectorisUnited Kingdom
-
Salus Ltd.UnknownRefractory Angina PectorisHungary
-
MedispecHadassah Medical OrganizationCompletedRefractory Angina PectorisIsrael
-
MedispecAcademisch Ziekenhuis MaastrichtCompletedRefractory Angina PectorisNetherlands
-
MedispecUniversität Duisburg-EssenUnknownRefractory Angina PectorisGermany
-
Consorzio Futuro in RicercaActive, not recruitingRefractory Angina PectorisItaly
-
MedispecHeart and Diabetes Center North-Rhine WestfaliaUnknownRefractory Angina PectorisGermany
-
Catharina Ziekenhuis EindhovenRecruitingRefractory Angina Pectoris | Spinal Cord StimulationNetherlands
-
MedispecKMH Cardiology and Diagnostic CentresSuspendedRefractory Angina PectorisCanada
-
Neovasc Inc.Shockwave Medical, Inc.RecruitingRefractory AnginaUnited States, Canada
Clinical Trials on Coronary Sinus Reducer device
-
Tel-Aviv Sourasky Medical CenterNeovasc Inc.Recruiting
-
Clinical Hospital Centre ZagrebRecruitingCoronary Artery Disease | Angina PectorisCroatia
-
Regional Cardiology Center, The Copper Health Centre...Recruiting
-
Imperial College LondonGuy's and St Thomas' NHS Foundation Trust; Liverpool University Hospitals NHS... and other collaboratorsRecruitingCoronary Disease | Angina Pectoris | Refractory Angina | Microvascular Angina | Microvascular Coronary Artery DiseaseUnited Kingdom
-
Imperial College LondonMedical Research Council; Imperial College Healthcare Nissen FundRecruitingRefractory AnginaUnited Kingdom
-
Kansas City Heart Rhythm Research FoundationNot yet recruitingHeart Failure With Reduced Ejection FractionUnited States
-
Oslo University HospitalNot yet recruiting
-
University Hospital Inselspital, BerneCompletedIschemia | Coronary Artery Disease | Circulation, Collateral | Coronary Sinus | Collateral Flow IndexSwitzerland
-
Johannes Gutenberg University MainzCompletedMicrovascular Coronary Artery DiseaseGermany
-
Sheba Medical CenterWithdrawnRe-entrant Atrioventricular Node TachycardiaIsrael